Form 4: Quanterix Executive Chair Receives Stock for Board Fees

William P. Donnelly, Executive Chair of Quanterix Corp, acquired 6,178 shares in lieu of cash compensation for his first-quarter board service.

Summary

• William P. Donnelly, the Executive Chair and a Director of Quanterix Corp (QTRX), acquired 6,178 shares of common stock on April 1, 2026.
• The shares were granted in lieu of cash fees for his service on the Board of Directors and its committees for the first quarter of 2026.
• The transaction was valued at $0.00 per share as it represents a compensation-based grant.
• Following this acquisition, Donnelly directly owns a total of 154,127 shares of Quanterix common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as slightly positive because it demonstrates continued insider commitment and cash preservation, though it is a routine administrative transaction.

Positives

• The Executive Chair is increasing his equity stake in the company, further aligning his interests with those of the shareholders.
• The company is preserving cash by paying board fees in equity rather than cash.
• The reporting person maintains a significant direct ownership position of over 154,000 shares.

Negatives

• The issuance of new shares results in a minor dilution of existing shareholder equity.

Risks

• No specific business or financial risks were disclosed in this ownership change filing.

Future Outlook

The filing does not provide specific forward-looking guidance, but the continued use of equity-based compensation for directors suggests a policy of maintaining high insider ownership and cash conservation.

Management Comments

• The stock was granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the first quarter of 2026.

Industry Context

StockSavvy.ai notes that Quanterix's practice of compensating board members with equity is standard among high-growth life sciences and diagnostic companies, as it preserves capital for R&D and commercialization while ensuring leadership is incentivized by share price performance.

Comparison to Industry Standards

• Quanterix's director compensation structure is consistent with peers in the life sciences tools sector, such as 10x Genomics and Akoya Biosciences, which frequently utilize equity grants to align board interests.
• The size of the grant is typical for executive-level board service in mid-cap biotechnology companies.

Corporate Governance

Related Party Transactions

• The grant of 6,178 shares to William P. Donnelly, the Executive Chair, constitutes a related party transaction as part of an executive compensation arrangement.

Stakeholder Impact

• Shareholders: Benefit from management's increased equity alignment and the company's cash preservation.
• Management: William P. Donnelly increases his direct ownership stake in the company.

Next Steps

• Continued service by William P. Donnelly as Executive Chair and Director.
• Future Form 4 filings are expected at the end of subsequent quarters for ongoing board compensation.

Key Dates

Recommendation

The filing reflects routine insider compensation and does not signal a change in company fundamentals or strategic direction. Investors should maintain their current outlook based on broader financial performance.

Keywords

Quanterix, QTRX, Insider Trading, Form 4, Executive Compensation, William P. Donnelly, Board of Directors, Equity Grant